Synergistic Therapeutic Effects of Prussian Blue Erbium-Doped Hydroxyapatite Nanoparticles in Photothermal Photodynamic Cancer Therapy
ACS Biomaterials Science & Engineering · 2025
DOI: 10.1021/acsbiomaterials.5c00027 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Biomaterials Science & Engineering, 2025. Verfasst von Thi Thuy Truong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Industry 4.0 Convergence Bionics Engineering, Department of Biomedical Engineering, Pukyong National University, Busan 48513, Republic of Korea. Hauptthemen laut MEDLINE: Ferrocyanides, Durapatite, Photochemotherapy, Nanoparticles. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Pukyong National University, National Research Foundation of Korea.
Abstract (Originalsprache)
This study explores the synergistic therapeutic potential of Prussian Blue Erbium-Doped Hydroxyapatite (PB-Er-HAp) bioceramics in the context of photothermal therapy (PTT) and photodynamic therapy (PDT) for cancer treatment, highlighting their role in multimodal therapeutic approaches and imaging. PB-Er-HAp nanoparticles (NPs) were synthesized using a facile coprecipitation method to incorporate erbium (Er) into nanostructured hydroxyapatite (HAp) at various concentrations. Prussian Blue (PB) was functionalized onto the surfaces of these NPs, resulting in a final particle size of less than 50 nm. The therapeutic efficacy of the synthesized 1.0 mol % PB-Er-HAp NPs was evaluated in vitro, using MDA-MB-231 breast cancer cells. In vitro studies demonstrated that the PB-Er-HAp NPs exhibited significant PTT and PDT effects under 808 nm laser irradiation, effectively inducing cancer cell death through heat generation and reactive oxygen species production, respectively. In vitro experiments validated the ability of NPs to inhibit tumor growth in the MDA-MB-231 breast cancer cell line. This study emphasizes the potential of PB-Er-HAp NPs as a versatile platform for synergistic cancer therapy, combining PTT and PDT effects, while offering capabilities for biomedical imaging. Future research aims to further optimize these NPs and explore their clinical application, aiming toward enhanced therapeutic outcomes in cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Industry 4.0 Convergence Bionics Engineering, Department of Biomedical Engineering, Pukyong National University, Busan 48513, Republic of Korea.
- Smart Gym-Based Translational Research Center for Active Senior's Healthcare, Pukyong National University, Busan 48513, Republic of Korea.
- University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, United States.
- Digital Healthcare Research Center, Pukyong National University, Busan 48513, Republic of Korea.
- Ohlabs Corp., Busan 48513, Republic of Korea.
ORCID-Profile: Junghwan Oh, Sudip Mondal
Förderung
- Pukyong National University
- National Research Foundation of Korea
Zitieren
APA
Truong, T. T., Doan, V. H. M., Nguyen, D. Q., Nguyen, Q. D., Choi, J., Subramaniyan, B., Ahn, J., Lee, B., Oh, J., & Mondal, S. (2025). Synergistic Therapeutic Effects of Prussian Blue Erbium-Doped Hydroxyapatite Nanoparticles in Photothermal Photodynamic Cancer Therapy. ACS Biomaterials Science & Engineering. https://doi.org/10.1021/acsbiomaterials.5c00027
Vancouver
Truong TT, Doan VHM, Nguyen DQ, Nguyen QD, Choi J, Subramaniyan B, et al. Synergistic Therapeutic Effects of Prussian Blue Erbium-Doped Hydroxyapatite Nanoparticles in Photothermal Photodynamic Cancer Therapy. ACS Biomaterials Science & Engineering. 2025. doi:10.1021/acsbiomaterials.5c00027
BibTeX
@article{Truong2025,
author = {Truong, Thi Thuy and Doan, Vu Hoang Minh and Nguyen, Dinh Quan and Nguyen, Quoc Dung and Choi, Jaeyeop and Subramaniyan, Bharathiraja and Ahn, Jaesung and Lee, Byeongil and Oh, Junghwan and Mondal, Sudip},
title = {Synergistic Therapeutic Effects of Prussian Blue Erbium-Doped Hydroxyapatite Nanoparticles in Photothermal Photodynamic Cancer Therapy},
journal = {ACS Biomaterials Science & Engineering},
year = {2025},
doi = {10.1021/acsbiomaterials.5c00027}
}
EUVIMED